Tambien se ha usado para tratar episodios graves de sangrado en pacientes con inhibidores del factor IX
Dr Harry Griffin, assistant director of the Roslin Institute, said: "Sheep like Polly and Molly have been genetically engineered to produce Factor IX
which is used to treat haemophilia in humans.
Hemophilia B, also known as Christmas disease, is the second most common type of hemophilia and results from insufficient amounts of clotting factor IX
, a naturally occurring protein in blood that helps to control bleeding.
People with haemophilia B have deficient blood clotting factor IX
activity that results in prolonged or spontaneous bleeding, especially into the muscles, joints or internal organs.
Alprolix [Coagulation Factor IX
(Recombinant), Fc Fusion Protein] is approved for the treatment of haemophilia B in the U.
8221; Likewise, “The VisuDep-F Frozen Factor IX
Deficient Plasma is intended for use as a substrate plasma in the quantitative determination of Factor IX
activity in citrated plasmas using a clot-based assay.
Beginning on the first anniversary of the agreement, Genetics Institute also maintains an option to collaborate on the development of adeno-associated virus delivery of the gene-encoding factor IX
to treat hemophilia B, which if developed would trigger additional payments to Targeted Genetics.
The implanted genes have so far functioned correctly, directing the production of factor IX
for at least 5 months--a long time in the typical 2-year life span of a mouse.
The study Coagulation Factor IX
(CAS 9001-28-9) Market Research Report 2011' presents an overview of the Coagulation Factor IX
market globally and regionally by contemplating and analyzing its parameters.
active substance: Human coagulation factor ix
(doe), - amount of active substance: 1000 iu, - pharmaceutical form: Vial, - packaging conditions: Unit dose, - maximum price: 400.
According to the company, SPK-9001 is a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX
variant enabling endogenous production of factor IX
Alprolix is a prolonged circulating recombinant factor IX
Fc fusion protein product candidate for people with haemophilia B.
DSM Pharmaceutical Products has signed a manufacturing agreement with Sanquin Blood Supply Foundation in The Netherlands for the commercial supply of a monoclonal antibody used for the recovery and purification of coagulation factor IX
from human blood.
At the American Society of Gene Therapy Meeting in June 2000, Cell Genesys reported that in non-human primate models of hemophilia B, therapeutic levels of factor IX
were restored following a single administration of AAV gene therapy to the liver.
Using the gutted shell of a common virus, each research team delivered copies of the gene for factor IX
to the dogs' liver or muscle cells.